1. Case report: Treatment with ensartinib shows good response to SQSTM1-ALK fusion in lung adenocarcinoma
- Author
-
Pandeng Wang, Zhuo Jiang, Jianji Guo, Tao Liu, Zhen Liu, Dongdong Wang, and Honglin Li
- Subjects
SQSTM1-ALK ,rearrangement ,lung cancer ,targeted therapy ,ensartinib ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Lung cancer is a prevalent malignancy, with the rearrangement of the anaplastic lymphoma kinase (ALK) gene being responsible for a minority of cases of non-small cell lung cancer (NSCLC). NSCLC patients harboring ALK fusion proteins demonstrate sensitivity to ALK tyrosine kinase inhibitors (TKIs). In this report, we describe the case of a female patient with metastatic lung adenocarcinoma, identified through NGS to carry a rare inverted SQSTM1-ALK (S5, A20) fusion. The patient received ensartinib as first-line therapy, resulting in a partial response (PR). At the time of publication, the patient’s condition remained favorable. We have, for the first time, identified the presence of SQSTM1-ALK fusion in pericardial effusion, with the favorable response to ensartinib validating the oncogenic potential of SQSTM1-ALK fusion. The substantial advancements and extensive utilization of NGS have facilitated the identification of rare fusion variants.
- Published
- 2024
- Full Text
- View/download PDF